Pre-Initiation ECG Testing for Pharma V2

Accelerate treatment initiation and patient care

Many drugs need an ECG analysis before prescription.
Idoven has developed a rapid ECG analysis program to eliminate barriers in the patient journey and accelerate treatment initiation

Request a demo

Patient
Isabella Fontaine

Normal Sinus Rhythm
66 BPM

Cardiology Team

By Idoven

Trusted Partners

Client impact

Idoven has been partnering with a top-5 pharma company in Spain for the last 2 years to deliver meaningful impact for their therapy

82 NPS (Net Promoter Score)*

From oncologists and sales reps, indicating strong satisfaction in dozens of hospitals in Spain

Project Break Even after 6 months

considering new patient initiations due to removing prescription barriers

<6 minutes

ECG reports delivered enabling immediate treatment decisions

Partner with Idoven. Schedule a demo today!

Benefits of using Idoven

Our program improves patient experience and prevents suboptimal treatments due to uncertain waiting times.

Patient

Patients experience seamless cardiac care without the need for extra visits or follow-ups for ECGs, simplifying their health journey

Doctors

Doctors gain immediate, actionable insights from ECG data, enabling them to make swift and precise clinical decisions within a single visit

Pharma

Pharmaceutical companies streamline treatment delivery with easy integration into clinical workflows, accelerating patient access to necessary therapies

Idoven’s mission is to prevent cardiovascular disease

Idoven has developed the world’s first cardiology-as-a-service platform powered by artificial intelligence that augments both a cardiologist’s and non-cardiology expert clinician’s ability to identify, triage and diagnose patients at scale.

The company counts partners such as AstraZeneca, Abbott, and GE Healthcare, FIFPRO, Google, Santander and Real Madrid Foundation. Idoven is backed by top-tier investors and business angels including Insight Partners, Northzone and Wayra (Telefónica), Iker Casillas, Pau Gasol, the Accel Starters program, and EIT Health.

For MedTech

For Life Sciences

Preventative Screening Programs

We partner with
leading organizations globally

Interested?

We are working with world-class research centres in cardiovascular research. Our R&D demonstrate scientific advances in cardiology and machine learning, published in high-impact factor journals such as Nature, Heart, European Heart Journal, Circulation and Europace.

Request a demo